Loren Data's SAM Daily™

FBO DAILY - FEDBIZOPPS ISSUE OF APRIL 25, 2018 FBO #5997
MODIFICATION

66 -- Brand Name or Equal ZEISS Axio Scan Z.1 system for Brightfield and Fluorescence detection.

Notice Date

4/23/2018
 

Notice Type

Modification/Amendment
 

NAICS

334516 — Analytical Laboratory Instrument Manufacturing
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
 

ZIP Code

20852
 

Solicitation Number

SBSS-N02RC82543-61
 

Archive Date

4/30/2018
 

Point of Contact

KATHY D. ELLIOTT, Phone: 240-276-5570, Jolomi Omatete, Phone: 2402766561
 

E-Mail Address

ELLIOTTK@MAIL.NIH.GOV, jolomi.omatete@nih.gov
(ELLIOTTK@MAIL.NIH.GOV, jolomi.omatete@nih.gov)
 

Small Business Set-Aside

N/A
 

Description

Issued By: National Cancer Institute (NCI), Office of Acquisitions (OA) http://www.nci.nih.gov or http://rcb.cancer.gov/rcb-internet/ Key Dates: Capability Statement Due Date: April 26, 2018 by 5:30PM EST This Small Business Sources Sought Notice (SBSS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this Sources Sought Notice is to identify qualified small business concerns including 8(a), HUBZone or Service-Disabled Veteran-owned business concerns that are interested in and capable of performing the work described herein. The NCI does not intend to award a contract on the basis of responses received nor otherwise pay for the preparation of any information submitted. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This requirement is assigned North American Industry Classification System (NAICS) code 334516 with a size standard of 1000 employees is being considered. As a result of this Sources Sought Notice, the NCI may issue a combined synopsis solicitation through FedBizOpps. THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NCI shall arise as a result of a response to this Sources Sought Notice or the NCI's use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. The purpose of this acquisition is to purchase Brand Name or Equal Bayer Healthcare ZEISS Axio Scan Z.1 system for Brightfield and Fluorescence detection. The NCI Laboratory of Tumor Immunology and Biology (LTIB) functions as a translational research program dedicated to the design and development of novel immunotherapeutic strategies for cancer treatment and prevention. A major effort in our laboratory is the study of novel combinations of cancer vaccines, cell-based therapies, checkpoint inhibitory antibodies, and a variety of immunomodulatory agents that impact the tumor phenotype and the number and activity of various anti-tumor immune cell types. These studies are being conducted in vivo in animal models, both with murine tumor models and human xenograft models. To understand the changes that are taking place at the tumor site when various combination immunotherapies are administered, the NCI laboratory is planning to evaluate tumor tissues (primary and metastasis) for the presence of CD4+ and CD8+ T lymphocytes, B and NK cells, and a range of other immune cells that could reduce the tumor response to immunotherapy, including macrophages, myeloid cells, and regulatory T cells. Moreover, the phenotype of the tumor will be also assessed. These studies require the use of multiple, fluorescently labeled antibodies for identification of each cell type, as well as the subsequent quantification of the number of each cell type and its location relative to the tumor cells. Such evaluation requires the scanning of the whole tissue slides in various fluorescent channels. Similar studies are being conducted with tumor biopsies obtained from patients included in ongoing immunotherapy clinical trials, at various treatment stages. These studies will help understand whether a particular immunotherapy combination is more effective at inducing an anti-tumor immune response Genomics Core. In addition, this study provides the NCI intramural investigators with a range of genomics technologies, available either as services delivered by the core, or as walk up access to specific instrumentation and technologies. The requested instrument will allow the NCI to: (1) Effectively obtain high quality digital images of these various analyses. (2) Archive the pathology images generated in digital form. (3) To quantitatively and comparatively evaluate the expression of the markers investigated. The following product features are required: -Magazine of 25 bays for holding up to 100 standard 1" x 3" slides -Scanner can be loaded with 100 slides and left to run automatically -Uninterrupted scanning with continuous slide introduction -High speed, high fidelity image digitization tool -Ability to scan 2"x3", 4"x3", and 28mm x 48mm Giessen format slides -Brightfield, Fluorescence, and Polarized Light sources -Dedicated Cameras for Pre-scan, Brightfield and Fluorescence -Barcode reading of slide labels -Automatic tissue detection and automatic focus strategy with adaptive focus point distribution -Multi-channel, multidimensional imaging -Ability to hold up to five objectives (2.5X, 5X, 10X, 20X, 40X) -10 filter positions - 9 filters for immunofluorescence with fast filter wheel option -Scanning of the full area of the slide -Multiple excitation and emission configurations with high-speed switching -Image processing, analysis and reporting including processing and comparison of up to 16 images in TIFF, JPEG, PNG and GIF format -Open Source ZEN Software allows analysis, annotation, and web-based archiving of images. Delivery/Installation: Delivery shall be within 60 days of purchase order award. All shipping /handling and delivery/installation fees shall be included. Installation shall be performed by, or under the direct supervision, of a certified operator. How to Submit a Response: 1. Page Limitations: Interested qualified small business organizations should submit a tailored capability statement for this requirement not to exceed 10 single sided pages including all attachments, resumes, charts, etc. (single spaced, 12 point font minimum) that clearly details the ability to perform the requirements of the notice described above. All proprietary information should be marked as such. Responses should include a minimum of a two pages demonstrating experience over the past two years meeting the requirements of this notice. Statements should also include an indication of current certified small business status; this indication should be clearly marked on the first page of your capability statement (preferable placed under the eligible small business concern's name and address). Responses will be reviewed only by NIH personnel and will be held in a confidential manner. 2. Due Date: Capability statements are due no later than 5:30PM EST on April 26, 2018. 3. Delivery Point: All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the unique specifications described herein. Written responses can be emailed to Kathy Elliott, Contract Specialist at Elliottk@mail.nih.gov or mailed to the address located under Point of Contact. All questions must be in writing and can be faxed to (240) 276-5399 or emailed. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, Contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA), through sam.gov. No collect calls will be accepted. Please reference number SBSS- N02RC82543-61on all correspondence. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, an RFQ may be published on FedBizOpps. However, responses to this notice will not be considered adequate responses to a solicitation(s). Point of Contact: Inquiries concerning this Notice may be direct to: Kathy Elliott 9609 Medical Center Dr., Room 1E226 Bethesda, MD 20892-9705 Elliottk@mail.nih.gov
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/SBSS-N02RC82543-61/listing.html)
 

Place of Performance

Address: 9000 Rockville Pike, Bethesdaa, Maryland, 20892, United States

Zip Code: 20892
 

Record

SN04897633-W 20180425/180423230543-a72ab580f575b821863d13c8fe82ba31 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |